Prof. Susan Lindquist has been named a recipient of the Albany Medical Center Prize in Medicine and Biomedical Research, according to the AP. Lindquist’s research has raised hopes that “treatments could prevent protein ‘misfolding’ that drives degenerative conditions like Alzheimer's, Parkinson's and Lou Gehrig's disease.”
Washington Post reporter Matt Schudel writes about the impact Prof. Emerita Suzanne Corkin’s work had on our understanding of memory and cognitive disorders. Schudel writes that Corkin, who died on June 4, “made significant contributions to the study of Alzheimer’s disease and Parkinson’s disease, and helped identify regions of the brain affected by degenerative disorders.”
MIT researchers have shown that memories can be restored using optogenetics, findings that could help treat Alzheimer’s. According to The Economist, the findings provide evidence “about how memories are lost during the early stages of the disease and may point to how…those memories might be brought back.”
A new study conducted by MIT researchers suggests that optogenetics could one day be used to help stimulate lost memories in Alzheimer’s patients, reports Ashley Welch for CBS News. Walsh writes that the researchers have “found evidence that ‘lost’ memories may just be inaccessible, with the potential to be retrieved.”
In an article posted by Scientific American, Sara Reardon writes that MIT researchers have shown that patients with Alzheimer’s can still form new memories and that lost memories could potentially be recalled using optogenetics. The findings “may allow more targeted stimulation, especially once researchers understand what happens to memories after they leave the hippocampus.”
Huffington Post reporter Ann Brenoff writes about a new MIT study that finds that Alzheimer’s patients may one day be able to recover lost memories using optogenetics. “The findings raise the hope — and possibility — that future treatments might indeed reverse some of the memory loss in early-stage Alzheimer’s patients.”
Washington Post reporter Ariana Eunjung Cha writes that MIT researchers have found evidence that memories lost due to Alzheimer’s disease could potentially be recalled using optogenetics. Cha writes that the research “raises the hope of future treatments that could reverse some of the ravages of the disease on memory.”
CBS Boston reports on a new study by MIT researchers that shows that memories lost due to Alzheimer’s disease may be recovered. The research shows “that while it may be hard for people with early Alzheimer’s to access memories, they are still retrievable.”
MIT researchers have found that cell stimulation may one day be a tool in helping Alzheimer’s patients recall lost memories, according to The Guardian. The findings raise “the possibility of future treatments that reverse memory loss in early stages of the disease.”
Boston Magazine reporter Jamie Ducharme writes that MIT researchers have developed a new digitized pen that could be used to improve a test that screens for Alzheimer’s and other cognitive impairments. “What the pen does is capture the writing with considerable temporal and spatial accuracy,” Prof. Randall Davis explains.
MIT researchers have developed a new tool that could be used to predict dementia earlier than is currently possible and with greater accuracy, reports Liat Clark for Wired. The researchers hope the new technique could be used to cut down on the number of “hours spent diagnosing, or potentially misdiagnosing, a disorder.”
Alexandra Ossola writes for Popular Science about a computer program created by MIT researchers that can aid in early detection of dementia by analyzing a patient’s drawings. The program “may enable doctors to diagnose patients much more quickly, and to intervene earlier to stave off the onset of cognitive degeneration.”
Wall Street Journal reporter Ed Silverman interviews Professor Andrew Lo about his proposal that a public-private partnership could solve funding issues for drugs research and development. “Right now, the risk of failure [in developing an Alzheimer’s treatment] is far too high for any single pharmaceutical company to take on,” Lo explains.
“Based on the current rates of success in creating new drugs for Alzheimer's disease, it could take 260 years until the next one is approved,” writes The Boston Globe’s Carolyn Johnson on the rationale for why Professor Andrew Lo is proposing a new, portfolio-based approach to Alzheimer's research.